2025 Japan Antipsychotic Drugs Revenue Opportunities Report
Description
The 2025 Japan Antipsychotic Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antipsychotic Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antipsychotic drugs market in Japan are Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly and Company, and Bristol-Myers Squibb Company. Otsuka Pharmaceutical is notable for marketing aripiprazole, a third-generation antipsychotic, in partnership with Bristol-Myers Squibb; aripiprazole is important due to its dopamine-serotonin stabilizing mechanism and better tolerability profile compared to older antipsychotics. Sumitomo Dainippon Pharma is also a key player, leveraging its strong presence in Japan. Eli Lilly ranks among leading companies globally and participates actively via its antipsychotic portfolio. These companies contribute significantly to the Japan schizophrenia drugs market, which generated USD 381.6 million in revenue in 2024, with second-generation antipsychotics being the largest segment by revenue.
In addition to marketing established drugs, these companies invest in research and development to enhance efficacy and reduce side effects, helping to meet growing demands in Japan. Second and third-generation antipsychotics dominate due to better patient outcomes and fewer adverse effects. The Japan antipsychotic market is expanding at a CAGR of 6.3%, driven by schizophrenia prevalence and increasing awareness. Other companies like H. Lundbeck and Janssen Pharmaceuticals also operate in Japan but are relatively smaller compared to the top four. The focus on advanced antipsychotics such as aripiprazole, brexpiprazole, and zotepine underlines the strategic emphasis on innovative therapies in Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antipsychotic Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antipsychotic drugs market in Japan are Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly and Company, and Bristol-Myers Squibb Company. Otsuka Pharmaceutical is notable for marketing aripiprazole, a third-generation antipsychotic, in partnership with Bristol-Myers Squibb; aripiprazole is important due to its dopamine-serotonin stabilizing mechanism and better tolerability profile compared to older antipsychotics. Sumitomo Dainippon Pharma is also a key player, leveraging its strong presence in Japan. Eli Lilly ranks among leading companies globally and participates actively via its antipsychotic portfolio. These companies contribute significantly to the Japan schizophrenia drugs market, which generated USD 381.6 million in revenue in 2024, with second-generation antipsychotics being the largest segment by revenue.
In addition to marketing established drugs, these companies invest in research and development to enhance efficacy and reduce side effects, helping to meet growing demands in Japan. Second and third-generation antipsychotics dominate due to better patient outcomes and fewer adverse effects. The Japan antipsychotic market is expanding at a CAGR of 6.3%, driven by schizophrenia prevalence and increasing awareness. Other companies like H. Lundbeck and Janssen Pharmaceuticals also operate in Japan but are relatively smaller compared to the top four. The focus on advanced antipsychotics such as aripiprazole, brexpiprazole, and zotepine underlines the strategic emphasis on innovative therapies in Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
